Camel milk proteins contain dipeptidyl peptidase IV (DPP-IV) inhibitory peptides. A camel whey protein concentrate (WPC, 44.7 ± 3.4% (w/w) protein) was prepared and subsequently hydrolysed with trypsin at different temperatures, enzyme to substrate (E:S) ratios and hydrolysis times yielding fifteen hydrolysates (H1–H15). Their DPP-IV half maximal inhibitory concentrations (IC₅₀) ranged from 0.55 ± 0.05 to 1.52 ± 0.16 mg L⁻¹ for H8 and H6, respectively. E:S was the only factor having a significant effect on the DPP-IV IC₅₀ value (p < 0.05). Relatively potent α-lactalbumin-derived DPP-IV inhibitory peptides (LAHKPL and ILDKEGIDY) were detected in selected hydrolysates. Additionally, three potent β-CN-derived peptides, VPV, YPI and VPF having DPP-IV IC₅₀ values of 6.6 ± 0.5, 35.0 ± 2.0 and 55.1 ± 5.8 µM, respectively, were identified. After IPI, VPV is the second most potent DPP-IV inhibitory peptide identified to date, which supports the role of camel milk as an antidiabetic agent.

骆驼奶蛋白包含二肽基肽酶IV（DPP-IV）抑制肽。制备骆驼乳清蛋白浓缩物（WPC，44.7±3.4％（w / w）蛋白质），然后在不同温度，酶与底物（E：S）的比例和水解时间下用胰蛋白酶水解，产生15种水解产物（H1-H15） 。对于H8和H6，它们的DPP-IV半数最大抑制浓度（IC ₅₀）分别为0.55±0.05至1.52±0.16 mg L ^-1。E：S是唯一影响DPP-IV IC ₅₀值的因素（p <0.05）。在选定的水解物中检测到相对有效的α-乳清蛋白衍生的DPP-IV抑制肽（LAHKPL和ILDKEGIDY）。另外，鉴定出三种有效的β-CN衍生肽，VPV，YPI和VPF，其DPP-IV IC ₅₀值分别为6.6± 0.5、35.0 ±2.0和55.1±5.8 µM。仅次于IPI，VPV是迄今为止鉴定出的第二强DPP-IV抑制肽，它支持骆驼奶作为抗糖尿病药的作用。